UY38766A - Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades - Google Patents

Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Info

Publication number
UY38766A
UY38766A UY0001038766A UY38766A UY38766A UY 38766 A UY38766 A UY 38766A UY 0001038766 A UY0001038766 A UY 0001038766A UY 38766 A UY38766 A UY 38766A UY 38766 A UY38766 A UY 38766A
Authority
UY
Uruguay
Prior art keywords
disease
imidazo
diseases
treatment
pyridinyl
Prior art date
Application number
UY0001038766A
Other languages
English (en)
Inventor
Zhili Xin
Anne Peterson Emily
Ryan Evans
May-Dracka Tricia
Fang Gao
Philippe Bolduc
Magnus Pfaffenbach
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of UY38766A publication Critical patent/UY38766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Derivados de Imidazo[1,2-a]piridinilo de fórmula (I’), o sales farmacéuticamente aceptables de estos, donde todas las variables son tal como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. Además, se proporciona un método para fabricar compuestos de la invención y métodos terapéuticos. La invención también proporciona métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y control de enfermedades o trastornos que incluyen enfermedad inflamatoria, enfermedad autoinmunitaria, cáncer, enfermedad cardiovascular, enfermedad del sistema nervioso central, enfermedad de la piel, afección y enfermedad oftálmica, y enfermedad ósea.
UY0001038766A 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades UY38766A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962867589P 2019-06-27 2019-06-27

Publications (1)

Publication Number Publication Date
UY38766A true UY38766A (es) 2021-01-29

Family

ID=71528117

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038766A UY38766A (es) 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Country Status (20)

Country Link
US (1) US20230087118A1 (es)
EP (1) EP3990454A1 (es)
JP (1) JP2022539373A (es)
KR (1) KR20220027196A (es)
CN (1) CN114245796B (es)
AR (1) AR119234A1 (es)
AU (1) AU2020301230A1 (es)
BR (1) BR112021026350A2 (es)
CA (1) CA3145040A1 (es)
CL (1) CL2021003452A1 (es)
CO (1) CO2022000659A2 (es)
CR (1) CR20220037A (es)
IL (1) IL289164A (es)
JO (1) JOP20210322A1 (es)
MA (1) MA56390A (es)
MX (1) MX2021015498A (es)
PE (1) PE20220578A1 (es)
TW (1) TW202115075A (es)
UY (1) UY38766A (es)
WO (1) WO2020263980A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911652A1 (en) * 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
KR20230134500A (ko) * 2020-12-22 2023-09-21 바이오젠 엠에이 인코포레이티드 Irak4 억제제로서의 이미다조[1,2-a]피리딘 유도체및 질환의 치료에서의 그의 용도
IL303931A (en) * 2020-12-22 2023-08-01 Biogen Ma Inc History of 2H-indazole as IRAK4 inhibitors and their use to treat diseases
KR20240035526A (ko) * 2021-07-07 2024-03-15 바이오젠 엠에이 인코포레이티드 Irak4 단백질의 분해를 표적하는 화합물
JP7555519B2 (ja) 2022-02-14 2024-09-24 アストラゼネカ・アクチエボラーグ Ｉｒａｋ４阻害剤
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MX340490B (es) * 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EP3187497A4 (en) * 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
EP3642199B1 (en) * 2017-06-21 2022-04-27 F. Hoffmann-La Roche AG Benzofurans as irak4 modulators

Also Published As

Publication number Publication date
BR112021026350A2 (pt) 2022-05-10
WO2020263980A1 (en) 2020-12-30
CL2021003452A1 (es) 2022-08-19
CN114245796A (zh) 2022-03-25
IL289164A (en) 2022-02-01
CN114245796B (zh) 2024-07-30
MX2021015498A (es) 2022-04-20
US20230087118A1 (en) 2023-03-23
AU2020301230A1 (en) 2022-01-06
JP2022539373A (ja) 2022-09-08
EP3990454A1 (en) 2022-05-04
CO2022000659A2 (es) 2022-04-29
CR20220037A (es) 2022-06-03
WO2020263980A8 (en) 2021-03-04
TW202115075A (zh) 2021-04-16
JOP20210322A1 (ar) 2023-01-30
KR20220027196A (ko) 2022-03-07
AR119234A1 (es) 2021-12-01
PE20220578A1 (es) 2022-04-20
CA3145040A1 (en) 2020-12-30
MA56390A (fr) 2022-05-04

Similar Documents

Publication Publication Date Title
UY38766A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
UY38765A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
ECSP19076732A (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
CY1117357T1 (el) Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων
PT1165085E (pt) Derivados de ftalazina para tratar doencas inflamatorias
CO2023009316A2 (es) Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
UY26332A1 (es) Nuevos derivados del ácido aminodicarboxílico con propiedades farmacéuticas.
UY28738A1 (es) Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa
SV2006002071A (es) Oxadiazolonas procedimientos para su preparacion y su uso como productos farmaceuticos
GB0606805D0 (en) Organic compounds
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
CO2023009313A2 (es) Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades
UY28647A1 (es) Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos
EP3903789A4 (en) THERAPEUTIC MEDICINE FOR A DISEASE ACCOMPANIED BY DISORDERS IN CELLS OF THE RETINAL SYSTEM OR RETINA TISSUE
MX2024005997A (es) Antagonistas del receptor de adenosina.
PE20231562A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO COMO INHIBIDORES DE IRAK4 Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2020061257A3 (en) Biological bits as computable elements within living systems